Commission Delegated Regulation (EU) 2024/197 of 19 October 2023 amending Regulation (EC) No 1272/2008 as regards the harmonised classification and labelling of certain substances
Date: 2023-10-19
Institutions: Directorate-General for Environment, European Commission
Subjects: classification, dangerous substance, environmental protection, labelling, lead, packaging, public health








L_202400197EN.000101.fmx.xml












Official Journal of the European Union


EN
Series L













2024/197


5.1.2024







            COMMISSION DELEGATED REGULATION (EU) 2024/197
of 19 October 2023
         
amending Regulation (EC) No 1272/2008 as regards the harmonised classification and labelling of certain substances
(Text with EEA relevance)


THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (1), and in particular Article 37(5) thereof,

Whereas:







(1)


Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains the list of harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to that Regulation.












(2)


Proposals to introduce harmonised classification and labelling of certain substances and to update the harmonised classification and labelling of certain other substances have been submitted to the European Chemicals Agency (the ‘Agency’) pursuant to Article 37 of Regulation (EC) No 1272/2008. The Committee for Risk Assessment of the Agency (RAC) adopted, after having taken account of the comments received from the parties concerned, the following opinions (2) on those proposals:






—


Opinion of 18 March 2021 concerning benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate;










—


Opinion of 18 March 2021 concerning benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis[phenol] (1:1);










—


Opinion of 18 March 2021 concerning reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate (1:1);










—


Opinion of 18 March 2021 concerning reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol (1:1);










—


Opinion of 18 March 2021 concerning 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol; bisphenol AF;










—


Opinion of 18 March 2021 concerning cinnamaldehyde; 3-phenylprop-2-enal; cinnamic aldehyde; cinnamal [1], (2E)-3-phenylprop-2-enal [2];










—


Opinion of 18 March 2021 concerning benfluralin (ISO); N-butyl-N-ethyl-α,α,α-trifluoro-2,6-dinitro-p-toluidine;










—


Opinion 18 March 2021 concerning 3,3'-dimethylbiphenyl-4,4'-diyl diisocyanate;










—


Opinion of 18 March 2021 concerning foramsulfuron (ISO); 2-{[(4,6-dimethoxypyrimidin-2-yl)carbamoyl]sulfamoyl}-4-formamido-N,N-dimethylbenzamide; 1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-dimethylcarbamoyl-5-formamidophenylsulfonyl)urea;










—


Opinion of 18 March 2021 concerning ethyl acrylate;










—


Opinion of 18 March 2021 concerning methyl acrylate;










—


methyl propenoate;










—


Opinion of 18 March 2021 concerning methyl methacrylate; methyl 2-methylprop-2-enoate; methyl 2-methylpropenoate;










—


Opinion of 18 March 2021 concerning transfluthrin (ISO); 2,3,5,6-tetrafluorobenzyl (1R,3S)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate;










—


Opinion of 18 March 2021 concerning allyl methacrylate; 2-methyl-2-propenoic acid 2-propenyl ester;










—


Opinion of 18 March 2021 concerning mepiquat chloride (ISO); 1,1-dimethylpiperidinium chloride;










—


Opinion of 10 June 2021 concerning triethylamine;










—


Opinion of 10 June 2021 concerning di-n-butylamine;










—


Opinion of 10 June 2021 concerning 4-nitrosomorpholine;










—


Opinion of 10 June 2021 concerning difenoconazole (ISO); 1-({2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-1,3-dioxolan-2-yl}methyl)-1H-1,2,4-triazole; 3-chloro-4-[(2RS,4RS;2RS,4SR)-4-methyl-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]phenyl 4-chlorophenyl ether;










—


Opinion 10 June 2021 concerning N,N-dimethyl-p-toluidine;










—


Opinion of 10 June 2021 concerning potassium chlorate;










—


Opinion of 10 June 2021 concerning sodium chlorate;










—


Opinion of 10 June 2021 Concerning reaction mass of 1-(2,3-epoxypropoxy)-2,2-bis ((2,3-epoxypropoxy)methyl) butane and 1-(2,3-epoxypropoxy)-2-((2,3-epoxypropoxy)methyl)-2-hydroxymethyl butane;










—


Opinion of 10 June 2021 concerning metribuzin (ISO); 4-amino-6-tert-butyl-3-methylthio-1,2,4-triazin-5(4H)-one; 4-amino-4,5-dihydro-6-(1,1-dimethylethyl)-3-methylthio-1,2,4-triazin-5-one;










—


Opinion 16 September 2021 concerning lithium carbonate [1] lithium chloride [2] lithium hydroxide [3];










—


Opinion of 16 September 2021 concerning dimethyl propylphosphonate;










—


Opinion of 16 September 2021 concerning dibutyltin maleate;










—


Opinion of 16 September 2021 concerning dibutyltin oxide;










—


Opinion of 16 September 2021 concerning clothianidin (ISO); (E)-1-(2-chloro-1,3-thiazol-5-ylmethyl)-3-methyl-2-nitroguanidine;










—


Opinion of 16 September 2021 concerning cymoxanil (ISO); 2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide;










—


Opinion of 16 September 2021 concerning nonylphenol, branched and linear, ethoxylated (with average molecular weight < 352 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof];










—


Opinion of 16 September 2021 concerning nonylphenol, branched and linear, ethoxylated (with 352 g/mol ≤ average molecular weight < 704 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof];










—


Opinion of 16 September 2021 concerning nonylphenol, branched and linear, ethoxylated (with 704 g/mol ≤ average molecular weight ≤ 1 540 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof];










—


Opinion of 16 September 2021 concerning 1-phenylethan-1-one (1-phenylethylidene)hydrazone;










—


Opinion of 16 September 2021 concerning 9-[2-(ethoxycarbonyl)phenyl]-3,6-bis(ethylamino)-2,7-dimethylxanthylium chloride; Basic Red 1;










—


Opinion of 16 September 2021 concerning picolinafen (ISO); N-(4-fluorophenyl)-6-[3-(trifluoromethyl)phenoxy]pyridine-2-carboxamide; 4′-fluoro-6-[(α,α,α-trifluoro-m-tolyl)oxy]picolinanilide;










—


Opinion of 16 September 2021 concerning diuron (ISO); 3-(3,4-dichlorophenyl)-1,1-dimethylurea;










—


Opinion of 16 September 2021 concerning diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide;










—


Opinion of 16 September 2021 concerning hydrogen sulphide, hydrogen sulfide;










—


Opinion of 16 September 2021 concerning benzyl alcohol;










—


Opinion of 16 September 2021 concerning resorcinol; 1,3-benzenediol;










—


Opinion of 16 September 2021 concerning 2,2',6,6'-tetrabromo-4,4'-isopropylidenediphenol; tetrabromobisphenol-A;










—


Opinion of 16 September 2021 concerning a reassessment at the request of the Commission to review the harmonised classification of lead (environment);










—


Opinion of 26 November 2021 concerning 2,2'-[[3-methyl-4-[(4-nitrophenyl)azo]phenyl]imino]bisethanol;










—


Opinion of 26 November 2021 concerning 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-1-ol;










—


Opinion of 26 November 2021 concerning 1,4-Benzenediamine, N,N’-mixed Ph and tolyl derivs.; Reaction mass of N-phenyl,N’-o-tolyl-phenylene diamine, N,N’-diphenyl-p-phenylene diamine and N,N’-di-o-tolyl-phenylene diamine;










—


Opinion of 26 November 2021 concerning tetramethylene dimethacrylate;










—


Opinion of 26 November 2021 concerning 7,7,9(or 7,9,9)-trimethyl-4,13-dioxo-3,14-dioxa-5,12-diazahexadecane-1,16-diyl bismethacrylate;










—


Opinion of 26 November 2021 concerning 2,2'-ethylenedioxydiethyl dimethacrylate;










—


Opinion of 26 November 2021 concerning bifenox (ISO); methyl 5-(2,4-dichlorophenoxy)-2-nitrobenzoate;










—


Opinion of 26 November 2021 concerning 4-methylimidazole;










—


Opinion of 26 November 2021 concerning sulfur dioxide;










—


Opinion of 26 November 2021 concerning 1,2-benzisothiazol-3(2H)-one; 1,2-benzisothiazolin-3-one;










—


Opinion of 26 November 2021 concerning benalaxyl (ISO); methyl N-(2,6-dimethylphenyl)-N-(phenylacetyl)-DL-alaninate.
















(3)


The Commission has received additional information from stakeholders contesting the scientific assessment set out in the RAC opinion of 26 November 2021 concerning 1,4-Benzenediamine, N,N’-mixed Ph and tolyl derivs. and in the RAC opinion of 16 September 2021 concerning dibutyltin oxide. The additional information has been assessed and has not been found sufficient to cast doubts on the scientific analysis contained in the RAC opinions. It is therefore appropriate to introduce the harmonised classification and labelling of the substances concerned on the basis of the assessment made in those opinions.












(4)


The RAC opinion of 16 September 2021 concerning the environmental toxicity of lead put forward various possible options to update the harmonised classification of lead for aquatic toxicity. These options give the possibility to either have a single entry for both lead in powder form (‘lead powder’) and in massive form (‘lead massive’) or to keep two separate entries, one for each form. However, as data for lead massive indicates a lower dissolution in water than for lead powder, a calculation in accordance with Part 4 of Annex I to Regulation (EC) No 1272/2008 leads to a less severe classification for lead massive. It is therefore appropriate to amend the existing aquatic toxicity classification for lead powder with regard to the M-factor and to introduce a different aquatic toxicity classification for lead massive.












(5)


In light of the RAC opinions, it is therefore appropriate to introduce or update the harmonised classification and labelling of the substances concerned on the basis of the assessment made in those opinions and following the further assessments.












(6)


Regulation (EC) No 1272/2008 should therefore be amended accordingly.












(7)


As regards the classification of methyl methacrylate as a respiratory sensitiser and the classification of lithium carbonate, lithium chloride and lithium hydroxide as reproductive toxic substances the Commission has received additional information from stakeholders after obtaining the RAC opinions of 18 March 2021 and of 16 September 2021 respectively concerning those substances. Since that new scientific information requires further assessment by RAC, methyl methacrylate, lithium carbonate, lithium chloride and lithium hydroxide recommended in the RAC opinions should not be subject to harmonised classification and labelling at this stage.












(8)


Compliance with the new or updated harmonised classifications should not be required immediately as a certain period of time is necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new or updated classifications and to sell existing stocks subject to the pre-existing regulatory requirements. That period of time is also necessary to allow suppliers sufficient time to take the actions required to ensure continuing compliance with other legal requirements following the changes made under this Regulation. Suppliers should, however, have the possibility to apply the new or updated harmonised classifications, and to adapt the labelling and packaging accordingly, on a voluntary basis before the date of application of this Regulation, to ensure a high level of protection of human health and of the environment and to provide sufficient flexibility to suppliers,





HAS ADOPTED THIS REGULATION:



Article 1
Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.


Article 2
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
It shall apply from 1 September 2025.
However, suppliers may already before that date classify, label and package substances and mixtures in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation.




This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels, 19 October 2023.


For the Commission


The President

Ursula VON DER LEYEN
            





(1)  
            OJ L 353, 31.12.2008, p. 1.

(2)  The opinions are accessible via the following website: https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/.The opinion of 16 September 2021 concerning a reassessment at the request of the Commission is accessible via the following website: https://echa.europa.eu/about-us/who-we-are/committee-for-risk-assessment/opinions-of-the-rac-adopted-under-specific-echa-s-executive-director-requests.




ANNEX
In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows:






(1)


the following entries are inserted following the order of the index numbers corresponding to each entry:















Index No


Chemical Name


EC No


CAS No


Classification


Labelling


Specific Conc. Limits, M- factors and ATE


Notes




Hazard Class and Category Code(s)


Hazard statement Code(s)


Pictogram, Signal Word Code(s)


Hazard statement Code(s)


Suppl. Hazard statement Code(s)




‘015-204-00-5


benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate


479-100-5


577705-90-9


Repr. 1B


H360F


GHS08
Dgr


H360F’


 


 


 




‘015-205-00-0


benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis[phenol] (1:1)


278-305-5


75768-65-9


Repr. 1B


H360F


GHS08
Dgr


H360F’


 


 


 




‘015-206-00-6


reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate (1:1)


—


—


Repr. 1B


H360F


GHS08
Dgr


H360F’


 


 


 




‘015-207-00-1


reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol (1:1)


—


—


Repr. 1B


H360F


GHS08
Dgr


H360F’


 


 


 




‘015-208-00-7


dimethyl propylphosphonate


242-555-3


18755-43-6


Muta. 1B
Repr. 1B


H340
H360Df


GHS08
Dgr


H340
H360Df’


 


 


 




‘050-034-00-5


dibutyltin maleate


201-077-5


78-04-6


Muta. 2
Repr. 1B
Acute Tox. 2
Acute Tox. 4
STOT RE 1
Skin Corr. 1
Eye Dam. 1


H341
H360FD
H330
H302
H372 (immune system)
H314
H318


GHS08
GHS06
GHS05
Dgr


H341
H360FD
H330
H302
H372 (immune system)
H314


 


inhalation:
ATE = 0,317 mg/L (dusts or mists)
oral:
ATE = 510 mg/kg bw’


 




‘050-035-00-0


dibutyltin oxide


212-449-1


818-08-6


Muta. 2
Repr. 1B
Acute Tox. 3
STOT RE 1
Skin Irrit. 2
Eye Dam. 1


H341
H360FD
H301
H372 (immune system)
H315
H318


GHS08
GHS06
GHS05
Dgr


H341
H360FD
H301
H372 (immune system)
H315
H318


 


oral:
ATE = 170 mg/kg bw’


 




‘603-244-00-1


reaction mass of 1-(2,3-epoxypropoxy)–2,2-bis ((2,3-epoxypropoxy)methyl) butane and 1-(2,3-epoxypropoxy)-2-((2,3-epoxypropoxy)methyl)-2-hydroxymethyl butane


—


—


Muta. 2
Repr. 1B


H341
H360F


GHS08
Dgr


H341
H360F’


 


 


 




‘603-245-00-7


2,2'-[[3-methyl-4-[(4-nitrophenyl)azo]phenyl]imino]bisethanol


221-665-5


3179-89-3


Skin Sens. 1


H317


GHS07
Wng


H317’


 


 


 




‘603-246-00-2


3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-1-ol


211-477-1


647-42-7


STOT RE 2
Aquatic Chronic 1


H373 (teeth, bones)
H410


GHS08
GHS09
Wng


H373 (teeth, bones)
H410


 


M = 1’


 




‘604-099-00-7


4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol; bisphenol AF


216-036-7


1478-61-1


Repr. 1B


H360F


GHS08
Dgr


H360F’


 


 


 




‘604-100-00-0


nonylphenol, branched and linear, ethoxylated (with average molecular weight ≤ 1 540  g/mol) [includes ortho-, meta-, para- isomers or any combination thereof]


500-315-8
500-024-6
500-045-0
500-209-1
248-762-5
243-816-4
248-291-5
—
230-770-5 248-743-1 247-555-7 248-293-6
—
and others


127087-87-0
9016-45-9
26027-38-3
68412-54-4
27986-36-3
20427-84-3
27176-93-8
1119449-38-5 7311-27-5 27942-27-4 26264-02-8 27177-05-5 14409-72-4 and others


Aquatic Acute 1
Aquatic Chronic 1


H400
H410


GHS09
Wng


H410


 


M = 1
M = 10’


 




‘606-155-00-6


cinnamaldehyde; 3-phenylprop-2-enal;
cinnamic aldehyde; cinnamal; [1]
(2E)-3-phenylprop-2-enal [2]


203-213-9 [1] - [2]


104-55-2 [1] 14371-10-9 [2]


Skin Sens. 1A


H317


GHS07
Wng


H317


 


Skin Sens. 1; H317: C ≥ 0,01 %’


 




‘607-766-00-0


tetramethylene dimethacrylate


218-218-1


2082-81-7


Skin Sens. 1B


H317


GHS07
Wng


H317’


 


 


 




‘607-767-00-6


7,7,9(or 7,9,9)-trimethyl–4,13-dioxo–3,14-dioxa–5,12-diazahexadecane–1,16-diyl bismethacrylate


276-957-5


72869-86-4


Skin Sens. 1B


H317


GHS07
Wng


H317’


 


 


 




‘607-768-00-1


2,2'-ethylenedioxydiethyl dimethacrylate


203-652-6


109-16-0


Skin Sens. 1B


H317


GHS07
Wng


H317’


 


 


 




‘607-769-00-7


bifenox (ISO); methyl 5-(2,4-dichlorophenoxy)-2-nitrobenzoate


255-894-7


42576-02-3


Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1


H302
H400
H410


GHS07
GHS09
Wng


H302
H410


 


oral:
ATE = 1 500  mg/kg bw
M = 1 000 
M = 1 000 ’


 




‘612-295-00-9


benfluralin (ISO); N-butyl-N-ethyl-α,α,α-trifluoro-2,6-dinitro-p-toluidine


217-465-2


1861-40-1


Carc. 2
Repr. 2
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H351
H361d
H315
H319
H317
H400
H410


GHS08
GHS07
GHS09
Wng


H351
H361d
H315
H319
H317
H410


 


M = 10
M = 10’


 




‘612-296-00-4



N,N-dimethyl-p-toluidine


202-805-4


99-97-8


Carc. 1B
Acute Tox. 4
Acute Tox. 3
STOT RE 2
Aquatic Chronic 3


H350
H332
H301
H373 (blood system, respiratory tract)
H412


GHS08
GHS06
Dgr


H350
H332
H301
H373 (blood system, respiratory tract)
H412


 


inhalation:
ATE = 1,4 mg/L (dusts or mists)
oral:
ATE = 140 mg/kg bw’


 




‘612-297-00-X


1-phenylethan-1-one (1-phenylethylidene)hydrazone


211-979-0


729-43-1


Skin Sens. 1


H317


GHS07
Wng


H317’


 


 


 




‘612-298-00-5


1,4-Benzenediamine, N,N’-mixed Ph and tolyl derivs.;


273-227-8


68953-84-4


Repr. 1B
Skin Sens. 1


H360FD
H317


GHS08
GHS07
Dgr


H360FD
H317’


 


 


 




‘613-346-00-8


4-nitrosomorpholine


—


59-89-2


Carc. 1B
Muta. 2
STOT RE 1


H350
H341
H372 (liver)


GHS08
Dgr


H350
H341
H372 (liver)


 


Carc. 1B; H350: C ≥ 0,001 %’


 




‘613-347-00-3


difenoconazole (ISO); 1-({2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl–1,3-dioxolan-2-yl}methyl)-1H-1,2,4-triazole; 3-chloro-4-[(2RS,4RS;2RS,4SR)-4-methyl-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]phenyl 4-chlorophenyl ether


—


119446-68-3


Carc. 2
Acute Tox. 4
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1


H351
H302
H319
H400
H410


GHS08
GHS07
GHS09
Wng


H351
H302
H319
H410


 


oral:
ATE = 1 450  mg/kg bw
M = 10
M = 10’


 




‘613-348-00-9


9-[2-(ethoxycarbonyl)phenyl]–3,6-bis(ethylamino)–2,7-dimethylxanthylium chloride; Basic Red 1


213-584-9


989-38-8


Acute Tox. 3
Eye Dam. 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H301
H318
H317
H400
H410


GHS06
GHS05
GHS09
Dgr


H301
H318
H317
H410


 


oral:
ATE = 280 mg/kg bw
M = 10
M = 1’


 




‘613-349-00-4


4-methylimidazole


212-497-3


822-36-6


Carc. 1B
Repr. 1B


H350
H360Fd


GHS08
Dgr


H350
H360Fd’


 


 


 




‘615-051-00-X


3,3'-dimethylbiphenyl–4,4'-diyl diisocyanate


202-112-7


91-97-4


Carc. 2
Resp. Sens. 1
Skin Sens. 1A


H351
H334
H317


GHS08
Dgr


H351
H334
H317


 


Skin Sens. 1A; H317: C ≥ 0,001 %’


 




‘616-241-00-5


foramsulfuron (ISO); 2-{[(4,6-dimethoxypyrimidin-2-yl)carbamoyl]sulfamoyl}-4-formamido-N,N-dimethylbenzamide; 1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-dimethylcarbamoyl-5-formamidophenylsulfonyl)urea


—


173159-57-4


Carc. 2
Aquatic Acute 1
Aquatic Chronic 1


H351
H400
H410


GHS08
GHS09
Wng


H351
H410


 


M = 1 000 
M = 100’


 




‘616-242-00-0


picolinafen (ISO); N-(4-fluorophenyl)-6-[3-(trifluoromethyl)phenoxy]pyridine-2-carboxamide; 4′-fluoro-6-[(α,α,α-trifluoro-m-tolyl)oxy]picolinanilide


—


137641-05-5


STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1


H373 (blood system, thyroid)
H400
H410


GHS08
GHS09
Wng


H373 (blood system, thyroid)
H410


 


M = 1 000 
M = 1 000 ’


 














(2)


the entries corresponding to index numbers 006-015-00-9; 015-203-00-X; 016-001-00-4; 016-011-00-9; 017-004-00-3; 017-005-00-9; 082-013-00-1; 082-014-00-7; 603-057-00-5; 604-010-00-1; 604-074-00-0; 606-034-00-8; 607-032-00-X; 607-034-00-0; 607-223-00-8; 607-246-00-3; 612-004-00-5; 612-049-00-0; 612-056-00-9; 613-088-00-6; 613-127-00-7; 613-307-00-5; 616-035-00-5; 616-104-00-X are replaced by the following entries respectively:















Index No


Chemical Name


EC No


CAS No


Classification


Labelling


Specific Conc. Limits, M-factors and ATE


Notes




Hazard Class and Category Code(s)


Hazard statement Code(s)


Pictogram, Signal Word Code(s)


Hazard statement Code(s)


Suppl. Hazard statement Code(s)




‘006-015-00-9


diuron (ISO); 3-(3,4-dichlorophenyl)–1,1-dimethylurea


206-354-4


330-54-1


Carc. 1B
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1


H350
H373 (blood system)
H400
H410


GHS08
GHS09
Dgr


H350
H373 (blood system)
H410


 


M = 100
M = 100’


 




‘015-203-00-X


diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide


278-355-8


75980-60-8


Repr. 1B
Skin Sens. 1B


H360Fd
H317


GHS08
GHS07
Dgr


H360Fd
H317’


 


 


 




‘016-001-00-4


hydrogen sulphide, hydrogen sulfide


231-977-3


7783-06-4


Flam. Gas 1A
Press. Gas
Acute Tox. 2
Aquatic Acute 1


H220
H330
H400


GHS02
GHS06
GHS09
Dgr


H220
H330
H400


 


inhalation: ATE = 440 ppmV (gases)


U’




‘016-011-00-9


sulphur dioxide; sulfur dioxide


231-195-2


7446-09-5


Press. Gas
Acute Tox. 3
STOT SE 1
Skin. Corr. 1B


H331
H370 (respiratory system) (inhalation)
H314


GHS04
GHS06
GHS08
GHS05
Dgr


H331
H370 (respiratory system) (inhalation)
H314


 


inhalation: ATE = 1 000  ppmV (gases)


U, 5’




‘017-004-00-3


potassium chlorate


223-289-7


3811-04-9


Ox. Sol. 1
Acute Tox. 3


H271
H301


GHS03
GHS06
Dgr


H271
H301


 


oral: ATE = 100 mg/kg bw’


 




‘017-005-00-9


sodium chlorate


231-887-4


7775-09-9


Ox. Sol. 1
Acute Tox. 3


H271
H301


GHS03
GHS06
Dgr


H271
H301


 


oral: ATE = 100 mg/kg bw’


 




‘082-013-00-1


lead powder;
[particle diameter < 1 mm]


231-100-4


7439-92-1


Repr. 1A
Lact.
Aquatic Acute 1
Aquatic Chronic 1


H360FD
H362
H400
H410


GHS08
GHS09
Dgr


H360FD
H362
H410


 


Repr. 1A;
H360D: C ≥ 0,03 %
M = 10
M = 100’


 




‘082-014-00-7


lead massive:
[particle diameter ≥ 1 mm]


231-100-4


7439-92-1


Repr. 1A
Lact.
Aquatic Chronic 1


H360FD
H362
H410


GHS08
GHS09
Dgr


H360FD
H362
H410


 


M = 10’


 




‘603-057-00-5


benzyl alcohol


202-859-9


100-51-6


Acute Tox. 4
Eye Irrit. 2
Skin Sens. 1B


H302
H319
H317


GHS07
Wng


H302
H319
H317


 


oral: ATE = 1 200  mg/kg bw’


 




‘604-010-00-1


resorcinol; 1,3-benzenediol


203-585-2


108-46-3


Acute Tox. 4
STOT SE 1
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1B
Aquatic Acute 1


H302
H370 (nervous system)
H315
H319
H317
H400


GHS07
GHS08
GHS09
Dgr


H302
H370 (nervous system)
H315
H319
H317
H400


 


oral: ATE = 500 mg/kg bw
M = 1’


 




‘604-074-00-0


2,2',6,6'-tetrabromo–4,4'-isopropylidenediphenol; tetrabromobisphenol-A


201-236-9


79-94-7


Carc. 1B
Aquatic Acute 1
Aquatic Chronic 1


H350
H400
H410


GHS08
GHS09
Dgr


H350
H410’


 


 


 




‘606-034-00-8


metribuzin (ISO); 4-amino-6-tert-butyl-3-methylthio-1,2,4-triazin-5(4H)-one; 4-amino-4,5-dihydro-6-(1,1-dimethylethyl)-3-methylthio-1,2,4-triazin-5-one


244-209-7


21087-64-9


Acute Tox. 4
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1


H302
H373 (blood system)
H400
H410


GHS07
GHS08
GHS09
Wng


H302
H373 (blood system)
H410


 


oral: ATE = 320 mg/kg bw
M = 10
M = 10’


 




‘607-032-00-X


ethyl acrylate


205-438-8


140-88-5


Flam. Liq. 2
Acute Tox. 3
Acute Tox. 4
Acute Tox. 4
STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1


H225
H331
H312
H302
H335
H315
H319
H317


GHS02
GHS06
Dgr


H225
H331
H312
H302
H335
H315
H319
H317


 


inhalation: ATE = 9 mg/L (vapours)
dermal: ATE = 1 800  mg/kg bw
oral: ATE = 1 120  mg/kg bw
STOT SE 3; H335: C ≥ 5 %
Skin Irrit. 2; H315: C ≥ 5 %
Eye Irrit. 2; H319: C ≥ 5 %


D’




‘607-034-00-0


methyl acrylate;
methyl propenoate


202-500-6


96-33-3


Flam. Liq. 2
Acute Tox. 3
Acute Tox. 4
Acute Tox. 4
STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1


H225
H331
H312
H302
H335
H315
H319
H317


GHS02
GHS06
Dgr


H225
H331
H312
H302
H335
H315
H319
H317


 


inhalation: ATE = 3 mg/L (vapours)
dermal: ATE = 1 100  mg/kg bw
oral: ATE = 500 mg/kg bw


D’




‘607-223-00-8


transfluthrin (ISO); 2,3,5,6-tetrafluorobenzyl (1R,3S)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate


405-060-5


118712-89-3


Carc. 2
Acute Tox. 4
STOT SE 1
Aquatic Acute 1
Aquatic Chronic 1


H351
H302
H370 (nervous system)
H400
H410


GHS08
GHS07
GHS09
Wng


H351
H302
H370 (nervous system)
H410


EUH066


oral: ATE = 580 mg/kg bw
M = 1 000 
M = 1 000 ’


 




‘607-246-00-3


allyl methacrylate;
2-methyl-2-propenoic acid 2-propenyl ester


202-473-0


96-05-9


Flam. Liq. 3
Acute Tox. 2
Acute Tox. 3
Acute Tox. 4
Aquatic Acute 1


H226
H330
H311
H302
H400


GHS02
GHS06
GHS09
Dgr


H226
H330
H311
H302
H400


 


inhalation: ATE = 1,5 mg/L (vapours)
dermal: ATE = 300 mg/kg bw
oral: ATE = 400 mg/kg bw’


 




‘612-004-00-5


triethylamine


204-469-4


121-44-8


Flam. Liq. 2
Acute Tox. 3
Acute Tox. 3
Acute Tox. 3
Skin Corr. 1A
Eye Dam. 1


H225
H331
H311
H301
H314
H318


GHS02
GHS06
GHS05
Dgr


H225
H331
H311
H301
H314


 


inhalation: ATE = 7,2 mg/L (vapours)
dermal: ATE = 300 mg/kg bw
oral: ATE = 100 mg/kg bw STOT SE 3; H335: C ≥ 1 %’


 




‘612-049-00-0


di-n-butylamine


203-921-8


111-92-2


Flam. Liq. 3
Acute Tox. 2
Acute Tox. 3
Acute Tox. 3
Skin Corr. 1B
Eye Dam. 1


H226
H330
H311
H301
H314
H318


GHS02
GHS06
GHS05
Dgr


H226
H330
H311
H301
H314


EUH 071


inhalation: ATE = 1,2 mg/L (vapours) dermal: ATE = 300 mg/kg bw
oral: ATE = 220 mg/kg bw’


 




‘612-056-00-9



N,N-dimethyl-m-toluidine; [1]

N,N-dimethyl-o-toluidine [2]


204-495-6 [1] 210-199-8 [2]


121-72-2 [1] 609-72-3 [2]


Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3


H331
H311
H301
H373 **
H412


GHS06 GHS08
Dgr


H331
H311
H301
H373 **
H412


 


*


C’




‘613-088-00-6


1,2-benzisothiazol-3(2H)-one; 1,2-benzisothiazolin-3-one


220-120-9


2634-33-5


Acute Tox. 2
Acute Tox. 4
Skin Irrit. 2
Eye Dam. 1
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1


H330
H302
H315
H318
H317
H400
H410


GHS06
GHS05
GHS09
Dgr


H330
H302
H315
H318
H317
H410


 


inhalation:
ATE = 0,21 mg/L (dusts or mists)
oral: ATE = 450 mg/kg bw
Skin Sens. 1A; H317: C ≥ 0,036 %
M = 1
M = 1’


 




‘613-127-00-7


mepiquat chloride (ISO); 1,1-dimethylpiperidinium chloride


246-147-6


24307-26-4


Acute Tox. 4
Acute Tox. 3
Aquatic Chronic 3


H332
H301
H412


GHS06
Dgr


H332
H301
H412


 


inhalation: ATE = 2,8 mg/L (dusts or mists)
oral:
ATE = 270 mg/kg bw’


 




‘613-307-00-5


clothianidin (ISO); (E)-1-(2-chloro–1,3-thiazol-5-ylmethyl)-3-methyl-2-nitroguanidine


433-460-1


210880-92-5


Repr. 2
Acute Tox. 4
STOT SE 1
Aquatic Acute 1
Aquatic Chronic 1


H361f
H302
H370 (nervous system)
H400
H410


GHS08
GHS07
GHS09
Dgr


H361f
H302
H370 (nervous system)
H410


 


oral: ATE = 390 mg/kg bw
M = 10
M = 100’


 




‘616-035-00-5


cymoxanil (ISO); 2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide; [1]
(2E)-2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide; [2]


261-043-0 [1]
- [2]


57966-95-7 [1]
166900-80-7 [2]


Repr. 2
Acute Tox. 4
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H361fd
H302
H373 (blood system, thymus, eyes)
H317
H400
H410


GHS08
GHS07
GHS09
Wng


H361fd
H302
H373 (blood system, thymus, eyes)
H317
H410


 


oral: ATE = 360 mg/kg bw
M = 1
M = 1’


 




‘616-104-00-X


benalaxyl (ISO); methyl N-(2,6-dimethylphenyl)-N-(phenylacetyl)-DL-alaninate


275-728-7


71626-11-4


Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1


H302
H400
H410


GHS07
GHS09
Wng


H302
H410


 


oral: ATE = 1 000  mg/kg bw
M = 1
M = 1’


 











ELI: http://data.europa.eu/eli/reg_del/2024/197/oj
ISSN 1977-0677 (electronic edition)